Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 290

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16G
Chunk 290
---

ITEM 16G.   CORPORATE GOVERNANCE
--------------------------------
 
Except as otherwise indicated, we are in compliance with corporate governance standards as currently applicable to us under Israeli, U.S., SEC and Nasdaq laws, rules and/or regulations, as applicable. Under the Nasdaq Listing Rules, as a foreign private issuer (as such term is defined in Rule 3b-4 under the Securities Exchange Act of 1934, as amended), we may elect to follow certain corporate governance practices permitted under the Companies Law in lieu of compliance with corresponding corporate governance requirements otherwise imposed by the Nasdaq Listing Rules for U.S. domestic issuers. We currently follow the provisions of the Companies Law, rather than the Nasdaq Listing Rules, solely with respect to the following requirements:
 

◾                             Quorum. As permitted under the Companies Law, pursuant to our articles of association, the                         
        quorum required for an ordinary meeting of shareholders consists of at least two shareholders present in person, by proxy or by other    
    voting instrument in accordance with the Companies Law, who hold at least 25% of the voting power of our shares (and in an adjourned meeting,
        with some exceptions, at least two shareholders), instead of 33 1/3% of the issued share capital, as required under the Nasdaq Listing   
                                                                        Rules.                                                                   
-------------------------------------------------------------------------------------------------------------------------------------------------

◾                      Executive sessions of independent directors. Israeli law does not require executive sessions                  
    of independent directors. Although all of our current directors are “independent directors” under the applicable Nasdaq criteria,
                      we do not intend to comply with this requirement if we have directors who are not independent.                 
-------------------------------------------------------------------------------------------------------------------------------------

◾                             Shareholder approval. We seek shareholder approval for all corporate actions requiring such                          
       approval under the Companies Law, which include (i) transactions with directors concerning the terms of their service or indemnification,   
         exemption and insurance for their service (or for any other position that they may hold at our company), (ii) transactions concerning     
         the compensation, indemnification, exculpation and insurance of the chief executive officer; (iii) the compensation policy recommended    
    by the compensation committee of our board of directors and approved by our board of directors (and any amendments thereto); (iv) extraordinary
         transactions with, and the terms of employment or other engagement of, a controlling shareholder (if and when this becomes relevant to    
             our company), (v) amendments to our articles of association, and